Breakthroughs are creating the potential to eradicate diseases and chronic health issues, from hepatitis C to obesity. Their success depends directly on the choice of pricing model, which ranges from:

• Per patient, with pharma companies and providers receiving payment for each intervention or treatment
• Per patient over time, which means the treatment regime has a price, usually independent of the number of interventions or treatments
• Per population: Pharma companies and providers are paid based on the entire population they could treat, independent of current symptoms or the number of treatments

Pharma companies play the Value Game, but the predominant per-patient model constrains their ability to share value.